A maker of medicines and vaccines, Pfizer produces well-known drugs like the blood thinner Eliquis, the Prevnar pneumonia vaccines, the Covid shot Comirnaty, the antiviral Paxlovid, and cancer treatments Ibrance and Xtandi, used by patients around the world. It was founded in 1849 in Brooklyn by German cousins Charles Pfizer, a chemist, and Charles Erhart, a confectioner, who began by coating a bitter worm medicine in almond-flavored toffee candy. Its most famous discovery, the erectile-dysfunction drug Viagra, was a happy accident—originally developed as a heart medication for angina.
Pfizer CFO Dave Denton to step down Aug 15, 2026; Cecile Guegan named interim CFO
Dave Denton will step down as Chief Financial Officer effective August 15, 2026, to pursue a professional opportunity in consumer goods outside the pharmaceutical industry.
Show detailsHide details
Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer effective August 16, 2026.
Denton's departure is not related to Pfizer's financial or operating results or any disagreements with the company.
Pfizer will conduct a comprehensive internal and external search for Denton's successor.
Guegan joined Pfizer in 2005 and has served in her current role since 2022; she led the integration of Seagen into Pfizer in 2024.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
Pfizer provides 2026 guidance and revises 2025 revenue guidance to ~$62.0B
Pfizer issued a press release on December 16, 2025, providing full-year 2026 guidance and revising full-year 2025 revenue guidance to approximately $62.0 billion from the prior range of $61.0 to $64.0 billion.
Show detailsHide details
Full-year 2026 revenue guidance is set at $59.5 to $62.5 billion, with COVID-19 product revenues expected to be about $1.5 billion lower than 2025 and a similar negative impact from loss of exclusivity.
Full-year 2026 adjusted diluted EPS guidance is $2.80 to $3.00, compared to reaffirmed 2025 adjusted diluted EPS guidance of $3.00 to $3.15.
Adjusted SI&A expenses for 2026 are guided at $12.5 to $13.5 billion, and adjusted R&D expenses at $10.5 to $11.5 billion, reflecting cost realignment and pipeline investment.
The report was furnished under Item 7.01 Regulation FD Disclosure, with the press release attached as Exhibit 99.1, and is not deemed filed for SEC purposes.
Pfizer will host a conference call on December 16, 2025, at 8:00 AM EST to discuss the guidance.
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Pfizer completes $6.0 billion multi-tranche notes offering on November 21, 2025
Pfizer Inc. completed a public offering of $6.0 billion aggregate principal amount of notes across seven tranches, including floating rate notes due 2027 and fixed-rate notes due 2027 through 2065.
Show detailsHide details
The offering included $500 million Floating Rate Notes due 2027, $1.0 billion 3.875% Notes due 2027, $1.0 billion 4.200% Notes due 2030, $1.25 billion 4.500% Notes due 2032, $1.25 billion 4.875% Notes due 2035, $500 million 5.600% Notes due 2055, and $500 million 5.700% Notes due 2065.
The notes were issued under a shelf registration statement on Form S-3 (Registration No. 333-277323) originally filed on February 23, 2024, as amended on May 13, 2025.
The notes were issued under an indenture dated September 7, 2018, as supplemented by a Sixth Supplemental Indenture dated November 21, 2025, with The Bank of New York Mellon as trustee.
The underwriting agreement and pricing agreement, dated November 18, 2025, were with Citigroup Global Markets Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, and Mizuho Securities USA LLC as representatives of the underwriters.
8.01 Other Events · 9.01 Financial Statements and Exhibits